索非布韦/维帕他韦
| 组成 | |
|---|---|
| 索非布韦 | NS5B聚合酶抑制剂 |
| 维帕他韦 | NS5A抑制剂 |
| 临床资料 | |
| 商品名 | Epclusa, Sofosvel, Velpanat, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a616034 |
| 核准状况 | |
| 怀孕分级 | |
| 给药途径 | 口服给药[2] |
| ATC码 | |
| 法律规范状态 | |
| 法律规范 |
|
| 识别信息 | |
| CAS号 | 1190307-88-0  1377049-84-7 |
| PubChem CID | |
| UNII | |
| KEGG | |
索非布韦/维帕他韦（Sofosbuvir/velpatasvir）用于治疗C型肝炎的口服复方药[2] [8] [7]。内含索非布韦和维帕他韦[2] [8]。它对基因型一至六的C型肝炎病毒的疗效超过 90%[2]。对同时合并肝硬化或艾滋病的C型肝炎患者也有效[2]。
此组合通常耐受性良好[2]。常见副作用包括头痛、疲倦、睡眠困难和恶心[9] [10]。目前尚无孕期和母乳哺育的相关研究[9]。对同时感染乙型肝炎的患者，需要格外小心[9]。索非布韦会阻断非结构蛋白5B蛋白，而维帕他韦则是阻断非结构蛋白5A蛋白[9]。
索非布韦/维帕他韦于 2016 年在美国和欧洲取得医疗使用许可[9] [8] [7]。名列世界卫生组织基本药物标准清单[11]。
参考文献
[编辑]- ^ Sofosbuvir / velpatasvir (Epclusa) Use During Pregnancy. Drugs.com. [13 December 2017]. （原始内容存档于14 December 2017）.
- ^ 2.0 2.1 2.2 2.3 2.4 2.5 Sofosbuvir/Velpatasvir for the treatment of Hepatitis C (PDF). WHO. [29 June 2017]. （原始内容存档 (PDF)于29 August 2021）.
- ^ Prescription medicines: registration of new chemical entities in Australia, 2016. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023].
- ^ Health Canada New Drug Authorizations: 2016 Highlights. Health Canada. 14 March 2017 [7 April 2024].
- ^ Epclusa 400 mg/100 mg film coated tablets. - Summary of Product Characteristics (SmPC). (emc). 4 November 2019 [1 March 2020]. （原始内容存档于2 March 2020）.
- ^ Epclusa- velpatasvir and sofosbuvir tablet, film coated. DailyMed. 21 November 2019 [1 March 2020]. （原始内容存档于16 March 2020）.
- ^ 7.0 7.1 7.2 Epclusa EPAR. European Medicines Agency (EMA). 27 February 2020 [1 March 2020]. （原始内容存档于2 March 2020）.
- ^ 8.0 8.1 8.2 Epclusa- velpatasvir and sofosbuvir tablet, film coated. DailyMed. 21 November 2019 [1 March 2020]. （原始内容存档于16 March 2020）.
- ^ 9.0 9.1 9.2 9.3 9.4 Sofosbuvir and Velpatasvir. The American Society of Health-System Pharmacists. [8 December 2017]. （原始内容存档于14 December 2017）.
- ^ FDA Approves New Treatment for Pediatric Patients with Any Strain of Hepatitis C. U.S. Food and Drug Administration (FDA) (新闻稿). 19 March 2020 [19 March 2020]. （原始内容存档于19 March 2020）.
- ^ World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
